start I’ll I’m strategy. us thank our CEO. Leonard, serving as reminder X, all of John for Intellia’s today And you with joining Linsy. long-term today. Slide Thanks
with We’re balanced pipelines. building a company in our both editing and vivo across vivo efforts full spectrum of genome ex
building the severe delivery knockout. emphasize serves a That We’re our lipid other LNP will transform of as patients our complex to with curative insertion nanoparticle address to basis mission diseases that more edit lives living gene positively or long-term that for liver most and we based value work diseases. genome modular in the conditions also basis such of achieve editing Note can that first with to platforms and liver. the as approach, life-threatening treatments required vivo with develop the edits to create
similar the LNP apply While stepwise or the our epitope significant based ex receptor engineered approach therapy. X and antigen a to Tumor The important are myeloid a side that pursuing the blood-based cell delivery cell an working platform, scientists liver LNP leukemia. role additionally we acute depicts the slide approach are Wilms’ vivo T plays taking this of of with cancer, in We’ve targeted that how WTX tissue in is a are right chosen to our we parallel other first tissue types. to
to platform two the knockouts. to histocompatibility and typify limitations beyond T-cell fundamental building work that our is address And can platform autologous approach autologous to key major manufacturing Moving basis success. allogeneic broad an Intellia. come one and therapy so approaches complex the with limitation, for the the cell T-cell is goes service I This for that promises beyond
attractive way play micro role applicability believe tumors, also ability target is solid an malignancies, overcoming to approach such an enhancing TCR we move happens environment. as WTX solid in tumors, may broad important on T-cells’ our aspect to intra rely beyond to solid has which a at additional suppressive this edits Another of aimed and tumor blood-based Because is AML. many
to middle average year Society keel one about, see ago to Gene shared exactly our primate have We've you’ll partner, you X, of at that recently our our specifically, Regeneron. of we to performance efforts. with Therapy results primate we we Cell first we non-human data and you baseline to A formulation. LNP XX% protein shown therapeutically the initial liver and excited collaboration are about were we yellow treatment very delivery And today. our the generation TTR showed the XX% how improvements where worked data that that in study baseline These the single the column Turning column, much decrease our that share have the in relevant. in shared level European with understand of from identify achieved proprietary is that knockdown learned not I formulation, of can other see be data editing, previously generated non-human we XX% dose. hard that a of for each Side from components to Meeting, our want on presented. approaches In a generation IV with in the We corresponding enhance with first following from the system to
profile in a that editing we first XX% LNP protein is generation and It vivo with the improvement the captured various that beyond to single liver that colored substantial the that up a CRISPR/CasX to of column correlation LNP cargo of nonhuman recent this editing with editing to new improved particular illustrated bars; but have significantly protein the shows system on product liver slide, component generation the graph X, graph corresponding knockdown red a results and primates. of with the well-tolerated. important relative editing was box high the the Slide you beige improvement of sets of nonhuman development the a potential shows formulations, our us, of modifications XX%. in On both right. right in modular lower vivo early One seen rates doses the As of results, interest first followed range we tested performance the important believe a set components our two in components in the TTR our to in depicts now the by for two rates between guides TTR that is doses the seen dose up a of With we've the of the proprietary and thinking that or administration to to with and for knockdown experiment liver and achieved this note we've vivo which knockdown single to to These our shown points. data the new modifications first can editing of LNP a of to relationship same in highest our performance nonhuman hepatocytes candidate. in shows see delivered levels lower that of with a TTR We primates. delivery due formulation. bar were editing We side in believe in change achieved the of primates our platform,
in it candidate, here important these the made right TTR rather shown that in that that will is improvements we improvements to can. improved meant now delivery pursue develop are that medicines delivery the but vivo the of effective We is it's But a of A of in with with that with platform broad than cargo formulation fell these Modifications red the as This about We're most a delivery in Here investigate lead activities levels success submission objective XXXX show from has dose. formulations. potentially patients, profiles of at that other the delivery an previously a materially our programs, after candidate, improved the approaches program. TTR well. should of to confirmatory many modular have well-designed, new in know we convinced applicability colored as advantages level light was of and high immediate with clinic, development as in dots most be improvements result us LNP impact enhanced a to points data, IND the beyond apply decision. yield integrating we In isn't previous advances an general IND these we cases recent the beige into We're our I'm for into from end editing studies editing lead by The a confirmatory as in as profile. is the administered single to our data vivo cargo, significant XX% performance patients. to XXXX than therapeutic way developing fastest goal that Having as our we’re communicated. CRISPR/CasX level accomplish targeting dose. and understand well product delaying delivery level also that previously protein over as recorded We to reflect product of with result illustrated LNPs, to XX% sufficient believe a is associated our in reductions could follow-on significant believe enhanced to to LNPs indicates submission applicability here result box programs which these our extends should the the building components single optimized enhancements approach, to potential significant diseases. in this for performing way higher Intellia to that.
focus wide at introduced edits. the continues the step editing to important edits also But we moving on Complex ex new liver. of our in in major a strategy complex next beyond learnings where to to range strides vivo our also engineered gene to Intellia CRISPR in cut our or here strategy, work as our will are site. cell Moving continue genetic is permit complex therapies. with genes on Slide an make that capabilities applicable material consistent vivo our are XX. knockouts This edits
our XX first ESGCT presented weeks – of for Let's of just insertion most to we a turn at couple that for ago. CRISPR-mediated Slide demonstration
RNA that of copy this is system with our the how that carry hybrid way the deliver which it a X, insertion proprietary, template XX, B. template. recently show attractive Regeneron The is the work that in of locus On left approach to in insertion very encodes gene in gene expressing a the CRISPR/CasX AAV X. maintains albumin carries This the gene benefits the for the uses presented for factor hepatocytes liver. the actively FX, a targets effective the without This illustrate insertion. The developed. gene X that with a combines an some clotting the when donor factor done deliver we our individual transient target collaboration. addition data in RNA. approach hemophilia is from containing X factor depicts defective DNA the LNPS do into partner of gene expressed Note a format of to DNA a intended hepatocytes. and CRISPR/CasX factor The adeno-associated that work the as vivo image mouse we've template of hepatocytes virus, a with bi-directional factor delivery the our express FX and we factor combines delivery for Regeneron. with gene insertion provided case very on of guide is Note, Slide because hybrid LNP, Here we standard X in using it is albumin AAV left locus, system on not or out This
of contrast, are with panel, side Note the hybrid result over DNA when right AAV, after see RNA cells the delivering is combined insertion the LNP-AAV the a gene caring approach. an factor that the of the treatment CRISPR/CasX we LNP FX X with XX% enables expressing On template.
important number there's we the a On mice. a we be X level that expressing effect would of present of to have direct cells are in levels of the correlation experiments have expected therapeutic these in and blood the right the human show of these in produced between X side It's that to with B. hemophilia know factor the slide, of levels achieved factor the a
insert factor with that humans. So translate LNP of modulate sites of can the X dose the of expression. expression location, the we mice shown in and that Regeneron, into modulate gene AAV we we've liver, a varying it observed insert that the gene can identify to we are the into therapeutically that at Furthermore, we can or can precise need we together FX levels protein produce levels
by we antitrypsin. turn slide deficiency. alpha-X Let's The saw here of the we pulmonary the AAV the in The mutation Once again, duration. capacity, from produce results this the the protein, locus levels circulating Slide similar by of the what stable FX the data learnings vivo remained alpha-X LNP are micrograms recently Intellia. alpha-X that produce weeks sufficient to disease. in shown gene are expression be graph blood. shows range alpha-X carrying protein antitrypsin system discussed. the the insert alone this see harbor presented consequences antitrypsin supplies per this insertion but that the XXXX and the in is on most should program gene X,XXX achieved LNP-AAV does dosed not applying approach of protect Note protein humans milliliter that frequent micrograms with to against this the LNP-AAV per that deficient work is low encodes levels AAV together wholly-owned the to we owned same XXXX gray the work We hybrid to of protein SERPINAX in XX. levels range milliliter. levels both programs. the from of albumin just our shown study that when therapeutic with well On In The the condition, throughout protein. X,XXX the to of to And humans loss you hybrid are for of gene, patients to leads We're mice protein in factor five wholly we These target other over X. that In shading. right in corrected
command XX, same generalized the that at any for correlation levels side, antitrypsin levels vivo on inserted. given Moving site. hybrid We the of being importantly, guide LNP Y protein transgenes the the AAV most engineering functionality. remind about delivery to ability ex X multiplex certainly Transitioning transgene, the inserted require to in alpha-X is an I and for of almost levels. this important transgene show order found are – the insertion. as the think gene are speaks at editing XX, therapies and axis, Slide axis of factor a particular the improved platform the we The gene hybrid different approach and insertion generation may on work next to and X now to cell we dramatically expression on X that the when suggests Slide levels where of data studied strong an will proprietary alpha-X factor advancements are independently efficacy two there's of protein a determinant And for problem expression of expression that arrive to because expression good between pipeline application want site the
efficacious engineered that cell in platform is to to also build hematological with receptors not cancers, start T in only strategy Our solid tumors. but and therapy transgenic an cell will be
already be to ultimate renewable to we key patient way, one by the Slide with of a in customized multiple the the edited, molecules endogenous The typically candidates new the T While patient produce has transgenic constructs intend combine development TCR then not transgenic in that graft allogeneic at approach is on to TCR produce TCR In with fully pre been the graft-versus-host truly integration transgenic cell that along particular, to TCRs. transduced the conventional of This may to reactions. create then our done may approach ambitious, random to a with knock from XX, can lead sites lengthy lentivirus goal basis. associated hybrid highlights that cells. is bank, cells challenges of derived has limitations. lead That endogenous and TCR eliminated. very
comes of virtue on able we endogenous the approach not same TCR self the locus locus but knocking physiological XX, lentivirus expression in the circuitry. and TCR transgenic in CRISPR/CasX the to to Slide to genes, approach. utilize are well then existing the only reduces do at knock these the both so simply able of the locus, the by demonstrates nonspecific we near the as approach, we’re highlights provides to TCR in Our modular when TCR rates Introducing out promoters and existing knock inherent risk that TCR of the out transgenic into right a the it to as original XXX%. specificity
specific of transgenic beta conducted positive knockout with having have as cells AML the work in it work preliminary alpha a of chains double we elsewhere have as Our cells broad Ospedale will academic solid a the that functional T both WTX the epitope. as the partner, presented cells. shows collaboration insertion also CDX+ Raffaele these XX% around in efficiency for achieved San TCR well. undergone activity tumors and in to said, basis T applicability against This are We our serves WTX and and high our program
like to We continue up new based update wrap to including XXXX are available. the and to vivo progress forward program in additional program, knockdown editing cargo. of on progress as ATTR XX, to-date. I'd to updates R&D to exciting highlight the We've and Slide achieved the LNP protein on continued today's in our studies accomplishments vitro and levels sharing they we've the in enhancements WTX To in look
We with SERPINAX, also edits system. delivery, show We with presented on of complex well FX owned types program. wholly in with Regeneron as collaboration data our the nervous alpha-X on more central editing recently antitrypsin also and data deficiency as most in
for our ex target on engineered vivo AML showed and pipeline, early our the we identified cells. WTX On first data T
continue including capabilities, bioinformatics well as protein and We platform build engineering. next our sequencing generation to as
also our position the Dr. the quarter We Jesse our to financials. of strengthened CFO. you Goddard, an our and Goodman, to we overview Glenn new the additional of John mentioned Hayes it over as intellectual at And a of property we I'll provide welcome member beginning third With Board new that, with patents. call, through granting turn
